Structure via PubChem · Public domain (PubChem)
etoricoxib
Sign in to saveAlso known as Arcoxia®, MK 0663, MK-0663, 5-chloro-6'-methyl-3-(p-(methylsulfonyl)phenyl)-2,3'-bipyridine, 5-Chloro-3-(4-methanesulfonyl-phenyl)-6'-methyl-[2,3']bipyridinyl, L791456
Etoricoxib, sold under brand names including Arcoxia, Exinef and Nucoxia is a selective COX-2 inhibitor developed and commercialized by Merck. It is approved in 63 countries worldwide as of 2007, except the United States where the Food and Drug Administration sent a Non Approvable Letter to Merck and required them to provide additional data.
Chemical data
- Formula
- C18H15ClN2O2S
- Molecular weight
- 358.8 g/mol
- IUPAC name
- 5-chloro-2-(6-methyl-3-pyridinyl)-3-(4-methylsulfonylphenyl)pyridine
- SMILES
- CC1=NC=C(C=C1)C2=C(C=C(C=N2)Cl)C3=CC=C(C=C3)S(=O)(=O)C
- InChIKey
- MNJVRJDLRVPLFE-UHFFFAOYSA-N
- XLogP
- 3.3
- Polar surface area
- 68.3 Ų
- H-bond donors
- 0
- H-bond acceptors
- 4
- Formal charge
- 0
via PubChem
Research
1,012 papers- Etoricoxib.Drugs · 2002
- Etoricoxib.Drugs of today (Barcelona, Spain : 1998) · 2004
- [Etoricoxib (Arcoxia)].Revue medicale de Liege · 2004
- Etoricoxib enhances aryl hydrocarbon receptor activity.Toxicology · 2023
- Etoricoxib: a highly selective COX-2 inhibitor.The Annals of pharmacotherapy · 2005
via PubMed
Wikidata facts
- Mass
- 358.054
Show 5 more facts
- chemical formula
- C₁₈H₁₅ClN₂O₂S
- World Health Organisation international non-proprietary name
- etoricoxib
- canonical SMILES
- CC1=NC=C(C=C1)C2=NC=C(C=C2C3=CC=C(C=C3)S(=O)(=O)C)Cl
- defined daily dose
- 60
- Commons category
- Etoricoxib
via Wikidata · CC0
~4 min read
Article
6 sectionsContents
- Medical uses
- Efficacy
- Adverse effects
- Mechanism of action
- Cardiovascular safety and concerns
- References
Etoricoxib, sold under brand names including Arcoxia, Exinef and Nucoxia is a selective COX-2 inhibitor developed and commercialized by Merck. It is approved in 63 countries worldwide as of 2007, except the United States where the Food and Drug Administration sent a Non Approvable Letter to Merck and required them to provide additional data.
It was patented in 1996 and approved for medical use in 2002.
Available in 25 languages
- Español
- Français
- Deutsch
- Русский
- Italiano
- العربية
- azb
- Bahasa Indonesia
- Bangla
- Central Kurdish
- Finnish
- Greek
- Hebrew
- Hungarian
- Macedonian
- Nederlands
- Norwegian
- Romanian
via Wikidata sitelinks · CC0